Rui Na Hao, 68Fremont, CA

2011028, Nov 24, 2011

Nov 18, 2009

13/129539

Jing Huang - Los Angeles CA, US
Rui Hao - Durham NC, US
Brett Eugene Lomenick - Los Angeles CA, US
Nao Jonai - Yokohama, JP
Simon Diep - Huntington Beach CA, US

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

A61K 31/713
A61K 31/5575
A61K 31/429
A61P 3/00
C12Q 1/34
G01N 33/566
C40B 30/04
C12Q 1/68
A61K 31/58
A61K 31/7088

514 44 A, 514173, 514559, 514368, 435 18, 435 792, 435 71, 506 9, 435 611

In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.

2010018, Jul 22, 2010

Nov 18, 2009

12/621290

JING HUANG - Los Angeles CA, US
Brett Eugene LOMENICK - Los Angeles CA, US
Rui HAO - Los Angeles CA, US
Nao JONAI - Yokohama, JP
Thomas M. VONDRISKA - Los Angeles CA, US
Sarah WARBURTON - Los Angeles CA, US
Gregory Joseph BAKER - Los Angeles CA, US
Mariam AGHAJAN - Los Angeles CA, US

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

C12Q 1/37
G01N 33/68

435 24, 204452, 204461

Drug affinity responsive target stability (DARTS) is a novel method of drug target ID with several significant advantages over current techniques. In certain embodiments the method involves contacting a sample comprising one or more protein target(s) with a test agent to form a sample/test agent mixture; contacting the mixture with a protease; and identifying a protein or protein fragment that is protected from proteolysis, wherein the protection from proteolysis is an indicator that the protein or protein fragment binds to or interacts with the test agent.

2023007, Mar 9, 2023

Sep 18, 2020

17/761088

- South San Francisco CA, US
Rui HAO - South San Francisco CA, US
Do Jin KIM - South San Francisco CA, US
Suresh PODA - South San Francisco CA, US
Rinkan SHUKLA - South San Francisco CA, US
Adam P. SILVERMAN - South San Francisco CA, US

C07K 16/18

In one aspect, antibodies that specifically bind to a human alpha-synuclein protein are provided. In some embodiments, an anti-alpha-synuclein antibody binds to monomeric human alpha-synuclein protein, oligomeric human alpha-synuclein protein, soluble human alpha-synuclein protein, human alpha-synuclein protein fibrils, and human alpha-synuclein protein that is phosphorylated at Ser129 (pSer129) with high affinity. In some embodiments, an anti-alpha-synuclein antibody can specifically bind to or immunodeplete alpha-synuclein protein. In some embodiments, an anti-alpha-synuclein antibody can prevent or inhibit alpha-synuclein seeding.

2020027, Sep 3, 2020

Sep 14, 2018

16/646536

- South San Francisco CA, US
Gilbert Di Paolo - South San Francisco CA, US
Rui Hao - South San Francisco CA, US
Joseph W. Lewcock - South San Francisco CA, US
Nathan Moerke - South San Francisco CA, US
Alicia A. Nugent - South San Francisco CA, US
Rishi Rakhit - South San Francisco CA, US
Ju Shi - South San Francisco CA, US
Rinkan Shukla - South San Francisco CA, US
Ankita Srivastava - South San Francisco CA, US
Bettina Van Lengerich - South San Francisco CA, US
Yin Zhang - South San Francisco CA, US

Denali Therapeutics Inc. - South San Francisco CA

C07K 16/28
A61P 25/28
C07K 16/40

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody increases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody decreases levels of sTREM2. In some embodiments, the antibody enhances TREM2 activity. In some embodiments, the antibody inhibits TREM2 activity.